XXXX : is it a surgical disease?

@entity1 @entity3123 @entity353 @entity706 @entity146 @entity5 @entity158 @entity3 @entity1893 @entity11612
Primary @entity11612 is a rare @entity5 that reportedly regresses promptly with @entity146 chemotherapy. Recently, the role of surgical management has been relegated to biopsy alone. The aim of this study was to review our experience with primary @entity11612 and to determine the outcome of @entity1 managed by radiation therapy and/or chemotherapy. From 1952 to 1991, 107 @entity1 with @entity1893 involving the pancreas were identified. Twelve @entity1 (11%) had primary @entity11612 . The presenting symptoms and signs were nonspecific: abdominal @entity158 (83%), @entity353 (50%), and a palpable mass (58%). Six of the 12 @entity1 (50%) undergoing celiotomy had a preoperative diagnosis of @entity3123 . These @entity706 were large (x = 8 +/- 2 cm) and deemed unresectable because of size, alleged mesenteric vessel encroachment, regional lymph node @entity3 , or because of an intraoperative diagnosis of @entity706 . Biopsy alone was performed in 50% of @entity1 and biliary bypass and/or gastroenterostomy was performed in 25% of @entity1 . A single resection (pancreatoduodenectomy) was performed 1 year after a full course of chemotherapy had failed. Ten @entity1 , all of whom died of progressive @entity706 , received primary postoperative radiation therapy and/or chemotherapy, and no @entity1 was disease-free at follow-up. Mean survival was 13 months for @entity1 who received chemotherapy alone (n = 2), 22 months for those treated with radiation therapy only (n = 5), and 26 months for those receiving combined radiation therapy and chemotherapy (n = 3).(ABSTRACT TRUNCATED AT 250 WORDS)
